Summary

An investigational, selective, orally active inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) failed to significantly reduce the risk for cardiovascular death, myocardial infarction, or stroke in stable coronary heart disease patients on optimal medical therapy. The design and results of the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy trial [STABILITY; The STABILITY Investigators. N Engl J Med 2014] are discussed in this article.